GlassScriptPhysician profile
Mimi G Bansal
NPI 1568563567
$2,808.79
in general payments reported to CMS, 2019-2025
28 companies · $530 in 2025
The $530 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $315 · 2020: $317 · 2021: $352 · 2022: $314 · 2023: $363 · 2024: $619 · 2025: $530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,511.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $602.42 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $372.93 | 2019-2023 | Xifaxan |
| Redhill Biopharma INC. | $346.80 | 2021-2024 | Talicia |
| Pfizer INC. | $221.36 | 2019-2025 | |
| Abbvie INC. | $161.94 | 2019-2020 | |
| Madrigal Pharmaceuticals | $154.26 | 2024-2025 | Resmetirom, Rezdiffra |
| Ardelyx, INC. | $128.20 | 2022-2023 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $110.75 | 2020-2025 | |
| Ironwood Pharmaceuticals, INC | $72.21 | 2019-2024 | |
| Allergan, INC. | $71.87 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $71.66 | 2022-2023 | Winlevi, Absorica Ld |
| Aimmune Therapeutics, INC. | $66.44 | 2023-2025 | Vowst |
| Nestle Healthcare Nutrition INC. | $57.28 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.08 | 2020-2024 | Gattex, Eohilia |
| Phathom Pharmaceuticals, INC. | $45.47 | 2024 | Voquezna |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $38.97 | 2023-2024 | Suflave, Sutab |
| Merz North America, INC. | $34.51 | 2020 | |
| Dermira, INC. | $26.26 | 2019 | |
| Genzyme Corporation | $24.02 | 2020 | |
| Incyte Corporation | $23.06 | 2022 | |
| Lilly USA, LLC | $17.53 | 2024 | Olumiant |
| Janssen Biotech, INC. | $16.76 | 2019 | |
| Evoke Pharma, INC. | $16.54 | 2023 | Gimoti |
| Vivus LLC | $15.96 | 2021 | |
| Arcutis Biotherapeutics, INC. | $15.89 | 2023 | |
| Genentech USA, INC. | $15.85 | 2019 | |
| Allegis Pharmaceuticals, LLC | $12.36 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mimi Bansal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.